Labcorp — Oct 24, 2024 release

• Subsequent to the quarter, announced an exclusive agreement with NowDiagnostics (NOWDx) to distribute the first over-the-counter, point-of-care Syphilis blood test granted marketing authorization by the FDA. On October 10, 2024, Labcorp announced a quarterly cash dividend of $0.72 per share of common stock, payable on December 13, 2024, to stockholders of record at the close of business on November 26, 2024. 2 LABCORP HOLDINGS INC. CONSOLIDATED RESULTS Three Months Ended Sep 30, Nine Months Ended Sep 30, 2024 2023 Delta 2024 2023 Delta Revenue Summary (Dollars in billions) Total Revenue $ 3.28  $ 3.06  7.4  % $ 9.68  $ 9.13  6.0  % Organic 4.2  % 3.4  % Base Business (1) 4.8  % 4.5  % COVID 19 Testing (2) (0.6  %) (1.1  %) Acquisitions net of Divestitures 3.1  % 2.4  % Foreign Exchange 0.1  % 0.2  % (1) Base Business includes Labcorp's operations except for COVID-19 Testing. (2) COVID-19 Testing represents COVID-19 PCR Testing. Earnings Summary (Dollars in millions, except per share data) Operating Income ("OI") $ 254.1  $ 252.3  $ 870.2  $ 848.4  OI as % of Revenue 7.7  % 8.3  % (50) bps 9.0  % 9.3  % (30) bps Adjustments (3) $ 187.0  $ 171.6  $ 503.6  $ 471.6  Adjusted Operating Income ("AOI") (4) $ 441.1  (5) $ 423.9  $ 1,373.8  $ 1,320.0  AOI as % of Revenue 13.4  % 13.9  % (40) bps (6) 14.2  % 14.5  % (30) bps Net Earnings from Cont. Ops $ 169.6  $ 183.6  $ 603.5  $ 547.2  Diluted EPS from Cont. Ops $ 2.00  $ 2.11  $ 7.13  $ 6.19  Adjusted EPS (4) $ 3.50  $ 3.38  $ 11.12  $ 10.26  (3) Adjustments include amortization, impairment charges, restructuring charges, and special items.